| Form type | Sec Links | Description | Filing date | Reporting date |
|---|
Form type | Sec Links | Description | Filing date | Reporting date |
|---|---|---|---|---|
| 20-F | Report | Data | 20-F | Mar 3, 2025 | Dec 31, 2024 |
| 6-K | Report | TOTAL VOTING RIGHTS | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Report | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Report | ANCHOR RESULTS PRESENTED AT 2025 AAAAI | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Mar 3, 2025 | Mar 3, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Feb 28, 2025 | Feb 28, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Feb 27, 2025 | Feb 27, 2025 |
| 6-K | Report | GSK PUBLISHES ANNUAL REPORT 2024 | Feb 27, 2025 | Feb 27, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 26, 2025 | Feb 26, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Feb 26, 2025 | Feb 26, 2025 |
| 6-K | Report | TRANSACTION IN OWN SHARES | Feb 25, 2025 | Feb 25, 2025 |
| 6-K | Report | GSK COMPLETES ACQUISITION OF IDRX, INC. | Feb 24, 2025 | Feb 24, 2025 |
| 6-K | Report | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME | Feb 24, 2025 | Feb 24, 2025 |
| 6-K | Report | DIRECTORATE CHANGE | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 21, 2025 | Feb 21, 2025 |
| 6-K | Report | NUCALA COPD SUBMISSION ACCEPTED IN CHINA | Feb 20, 2025 | Feb 20, 2025 |
| 6-K | Report | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA | Feb 18, 2025 | Feb 18, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 13, 2025 | Feb 13, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Feb 11, 2025 | Feb 11, 2025 |
| 6-K | Report | FINAL RESULTS | Feb 5, 2025 | Feb 5, 2025 |
| 6-K | Report | TOTAL VOTING RIGHTS | Feb 3, 2025 | Feb 3, 2025 |
| 6-K | Report | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN | Jan 28, 2025 | Jan 28, 2025 |
| 6-K | Report | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB | Jan 28, 2025 | Jan 28, 2025 |
| 6-K | Report | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION | Jan 27, 2025 | Jan 27, 2025 |
| 6-K | Report | JEMPERLI EXPANDED APPROVAL IN THE EU | Jan 21, 2025 | Jan 21, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Jan 16, 2025 | Jan 16, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Jan 15, 2025 | Jan 15, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Jan 14, 2025 | Jan 14, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Jan 13, 2025 | Jan 13, 2025 |
| 6-K | Report | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | Jan 13, 2025 | Jan 13, 2025 |
| 6-K | Report | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | Jan 10, 2025 | Jan 10, 2024 |
| 6-K | Report | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | Jan 7, 2025 | Jan 7, 2024 |
| 6-K | Report | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | Jan 3, 2025 | Jan 3, 2025 |
| 6-K | Report | TOTAL VOTING RIGHTS | Jan 2, 2025 | Jan 2, 2025 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Dec 23, 2024 | Dec 23, 2024 |
| 6-K | Report | BLOCK LISTING APPLICATION | Dec 20, 2024 | Dec 20, 2024 |
| 6-K | Report | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | Dec 20, 2024 | Dec 20, 2024 |
| 6-K | Report | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | Dec 16, 2024 | Dec 16, 2024 |
| 6-K | Report | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | Dec 16, 2024 | Dec 16, 2024 |
| 6-K | Report | JEMPERLI RECEIVES POSITIVE CHMP OPINION | Dec 16, 2024 | Dec 16, 2024 |
| 6-K | Report | DIRECTOR/PDMR SHAREHOLDING | Dec 12, 2024 | Dec 12, 2024 |
| 6-K | Report | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | Dec 9, 2024 | Dec 9, 2024 |
| 6-K | Report | BLENREP COMBINATION CHINA FILING ACCEPTANCE | Dec 9, 2024 | Dec 9, 2024 |
| 6-K | Report | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | Dec 9, 2024 | Dec 9, 2024 |
| 6-K | Report | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | Dec 5, 2024 | Dec 5, 2024 |